To become the world-leading developer of novel drugs for tumor immunotherapy
Core values of us
The values we believe in and also the codes of conduct we practice every day:
- · Honest and diligent
- · Open-minded and inclusive
- · Humble and resilient
- · Committed to becoming outstanding
To develop novel drugs with good efficacy and low cost for doctors and patients; to create an excellent environment for employees to advance harmoniously, and create ever-increasing value for shareholders.
Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. Oricell has raised over $120 million USD in series B financing in July 2022.
OriCell Therapeutics has made a large investment in the construction of synergistic innovative product R&D technology platforms. Its long-term development strategy is to focus on the global unmet clinical needs for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer, and develop innovative cellular drugs and bispecific antibodies with high clinical values. Adhering to the vision of "becoming the world-leading developer of novel drugs for tumor immunotherapy", OriCell Therapeutics will continue to explore and make efforts to provide patients and doctors with safer and more effective tumor treatment solutions, and help patients "restore health and reset vitality".
Focus on the development of independent innovation product pipelines
At present, 10 independent innovation pipelines for cellular drugs and bispecific antibodies targeting solid tumors have been established. Six products for tumor immunotherapy have entered the stage of clinical development, and two core IND applications are currently underway.
We have reached a global development agreement with ANTENGENE (B.6996) regarding our independently developed bispecific antibody, which is worth 142 million USD. Presently, the program has received approvals and is under way in Australia, the U.S. and China for phase I clinical trial.
The first CAR-T product developed by the company, targeting GPC-3 received positive data from an exploratory clinical study, which was presented at ASCO 2021. The product then received IND approval from NMPA in September 2022.
Our proprietary CAR-T cell therapy targeting GPRC5D (OriCAR-017) for the treatment of Relapsed/Refractory Multiple Myeloma (R/R MM) reported in oral presentation at ASCO 2022 annual meeting and the product has received orphan drug designation by US FDA. Its follow-up data was published on Lancet Haematology in Janurary 2023.
We own a B+A production and preparation center, an R&D center, and a quality inspection center, which collectively cover an area of 5000 m2.
Clinical-grade B+A production and preparation center
Committed to establishing a fully automated, modularized and closed-type preparation and production environment, providing various types of research-grade, clinical-grade and traceable cell products.
Complete quality control system
We have established standardized clinical operation protocols for biotherapy and standardized laboratory management policies, so as to improve the operating procedures and quality control specifications of each project.
Construction and planning of phase II clinical research facilities and commercial plants
At present, the company has started the construction of a commercial production center in Life Science Blue Bay of Shanghai Lin-gang Special Area, covering an area of 31 acres, with a total investment of about 1 billion yuan, to accelerate the commercialization of immuno-oncology products. It is expected to pass EU GMP and China GMP certification and put into operation in 2023;
International market development plan
In the future, the company plans to establish R&D, clinical research, and commercial operation centers in United States and other major international markets.
Continuous expansion of production sites and upgrade of environmental equipment to improve quality and efficiency